BMS Research to Highlight Role of Opdivo-Based Approaches in GU Cancers at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Reno, Nevada (UroToday.com) -- At ASCO GU 2023 (February 16-18), BMS will present several datasets supporting the potential of Opdivo(nivolumab) alone or in combination with other agents to improve patient outcomes across genitourinary tumor types, treatment settings and stages of disease. The following key data will be expanded upon at the symposium:

• CheckMate -274 (Abstract #LBA443): Late-breaking three-year follow-up results evaluating Opdivo for the adjuvant treatment of muscle-invasive urothelial carcinoma, which have great relevance for patients given that disease recurrence typically occurs within the first three years after radical resection.

• CheckMate -9ER (Abstracts #603 & #608): Three-year update and biomarker analyses evaluating Opdivo in combination with Exelixis’/Ipsen’s CABOMETYX (cabozantinib) for the first-line treatment of advanced renal cell carcinoma, which represents the longest reported follow-up in any Phase 3 trial with an immunotherapy-tyrosine kinase inhibitor regimen in this population. 

• COSMIC-313 (Abstract #605): Outcomes by IMDC risk from the Phase 3 study evaluating Exelixis’ CABOMETYX in combination with Opdivo and Yervoy (ipilimumab) versus Opdivo plus Yervoy in patients with previously untreated advanced intermediate- or poor- risk renal cell carcinoma, further supporting the importance of collaboration to broaden the number of patients who may be able to benefit from novel treatment combinations.

• CheckMate -650 (Abstract #22): Additional results from the Phase 2 trial evaluating Opdivo plus Yervoyfor post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC), supporting our commitment to researching combination approaches that may help improve outcomes for patients in need of new treatment options.